NCIC CLINICAL TRIALS GROUP

BRAIN
DISEASE SITE COMMITTEE MEETING
AGENDA

OPEN SESSIONS

Venue: Carlyle Room
Date: Saturday, April 28th 2012
Time: 9:00 a.m. – 12:00 p.m.
Chair: Dr. Warren Mason

9:00 am  WELCOME AND INTRODUCTIONS
          W. Mason

COMPLETED STUDIES

9:05 am  IND.162: A Phase I/II study of Temozolomide and RAD001c in Patients with Malignant Glioblastoma Multiforme - Final report and manuscript status
          W. Mason

TRIALS CLOSED TO ACCRUAL

9:10 am  CE5 (EORTC 22033-26033): Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study
          W. Mason

CE.5S: The Socio/behavioural Effects of Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study
          A. Leis

ACTIVELY ACCRUING TRIALS

9:30 am  CE.6: A Randomized Phase III Study of Temozolomide and Short-Course Radiation versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients
          N. Laperriere & J. Perry

9:45 am  CEC.1 (EORTC 26053_22054): Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial
          W. Mason & C. O’Callaghan

10:00 am  CEC.2 (NCCTG N0577): Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma (CODEL Trial)
          G. Cairncross
ACTIVELY ACCRUING TRIALS (CONTINUED)

10:30 am  **CEC.3 (NCCTG N107C)**: A phase III trial of post-surgical stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for resected metastatic brain disease

10:45 am  **IND.204**: PX866 in Recurrent GBM

APPROVED TRIALS PENDING ACTIVATION

11:00 am  **CEC.4 (ECOG E3F05)**: Phase III study of radiotherapy +/- temozolomide for symptomatic or progressive low-grade gliomas

MISCELLANEOUS

11:15 am  Terry Fox Research Institute (TRFI) Grant: Therapeutic Targeting of GBM Project Status Report

11:30 am  Translational Studies and Tumour Banking

11:45 am  Report from IND Committee

12:00 pm  **CLOSING REMARKS**